MicroStrategy
MSTR
NVIDIA
NVDA
Adobe
ADBE
Salesforce
CRM
Apple
AAPL
US Stock MarketDetailed Quotes
TARS Tarsus Pharmaceuticals
- 52.910
- +0.910+1.75%
Close Dec 20 16:00 ET
- 52.660
- -0.250-0.47%
Post 18:26 ET
2.02BMarket Cap-14.11P/E (TTM)
53.620High50.200Low816.37KVolume50.520Open52.000Pre Close42.87MTurnover2.81%Turnover RatioLossP/E (Static)38.23MShares56.77052wk High8.52P/B1.54BFloat Cap18.99052wk Low--Dividend TTM29.01MShs Float63.690Historical High--Div YieldTTM6.58%Amplitude10.800Historical Low52.509Avg Price1Lot Size
About Tarsus Pharmaceuticals Company
Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.
Company Profile
SymbolTARS
Company NameTarsus Pharmaceuticals
Listing DateOct 16, 2020
Issue Price16.00
Founded2017
CEODr. Bobak Azamian, M.D.,PhD
MarketNASDAQ
Employees244
Fiscal Year Ends12-31
Address15440 Laguna Canyon Road,Suite 160
CityIrvine
ProvinceCalifornia
CountryUnited States of America
Zip Code92618
Phone1-949-409-9820
Websitehttp://tarsusrx.com
Company Executives
- Name
- Position
- Salary
- Dr. Bobak Azamian, M.D.,PhD
- Chairman of the Board, President and Chief Executive Officer
- 3.13M
- Dr. Seshadri Neervannan, PhD
- Chief Operating Officer
- 1.74M
- Dr. Elizabeth Yeu-Lin, M.D.
- Chief Medical Officer
- 180.21K
- Dianne C. Whitfield
- Chief Human Resources Officer
- --
- Aziz Mottiwala, M.B.A.
- Chief Commercial Officer
- --
- Jeffrey S. Farrow
- Chief Financial Officer and Chief Strategy Officer
- 3.99M
- Dr. William J. Link,PhD
- Independent Director
- 183.33K
- Wendy L. Yarno, M.B.A.
- Lead Independent Director
- 265.83K
- Scott Morrison
- Independent Director
- 186.46K
- Rosemary A. Crane, M.B.A.
- Independent Director
- 183.71K
- Dr. Bhaskar Chaudhuri,PhD
- Independent Director
- 178.58K
- Dr. Andrew Goldberg, M.D.
- Independent Director
- 171.71K
- Dr. Bryan Wahl, J.D.,M.D.
- General Counsel and Secretary
- --
Trending US Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries
Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.